According to FutureWise analysis the chronic kidney disease diagnostics market in 2025 is US$ 1.28 billion, and is expected to reach US$ 2.11 billion by 2033 at a CAGR of 6.45%. The global rise in diabetes and hypertension, major risk factors for chronic kidney disease (CKD), is increasing the demand for early diagnostic solutions. Innovations in biomarker tests and point-of-care diagnostics are enhancing the early detection and monitoring of kidney function.
Chronic kidney disease symptoms like blood in urine, swollen joints, foamy urine, etc are seldom noticed by patients resulting in progressive loss of kidney functions and ultimately renal failure. Delayed diagnosis, lack of sufficient epidemiological data, the significant cost involved in end-stage renal diseases as well as mild kidney diseases have resulted in a substantial need for chronic kidney disease diagnostics. Apart from physical examination by healthcare professionals, certain diagnostics like biopsy or procedures like blood and urine test provide vital stats and early signs about patients neurological, blood vessels and organ conditions. Based on such diagnostic results healthcare professionals can effectively control the kidney symptoms and avoid the progression of chronic kidney disease in their patients.
Factors boosting the chronic kidney disease diagnostics market:
- Rising prevalence of kidney diseases
- Increase in diabetic patients’ population
- Investments into R D for kidney diseases diagnostic techniques
- The ever-emerging healthcare sector
- Extensive use of processed food containing excess potassium and
- The technological advancements in the healthcare diagnostics sector
Besides increased susceptibility of the ageing population due to degrading immune system, diabetics, cardiovascular issues are expected to fuel the growth of the global chronic kidney diseases diagnostics market during the forecast period.
Emergence of Novel Biomarkers: Traditional biomarkers such as serum creatinine and estimated glomerular filtration rate (eGFR) are being supplemented by new biomarkers that provide more accurate early detection of chronic kidney disease (CKD). These new tools include urinary biomarkers and multi-omics approaches that enhance diagnostic precision.
Integration of Artificial Intelligence (AI): AI-driven diagnostic tools are being developed to analyze complex datasets, including imaging and genetic information, to predict the progression of CKD and personalize treatment plans.